Figure 5
From: Specific effects of bortezomib against experimental malignant pleural effusion: a preclinical study
Tailored bortezomib treatment down-regulates NF- κ B-dependent paracrine mediator expression of pleural lung adenocarcinoma. Pleural fluid, blood, and pleural tumor tissue NF-κ B-dependent gene product levels were determined in samples obtained at day 14 from mice with MPE enrolled in control (n = 10), bortezomib prevention (n = 10), and bortezomib regression (n = 7) trials as in Figure 3C-D. TNF, tumor necrosis factor; CXCL, C-X-C motif chemokine ligand; CCL, C-C motif chemokine ligand. Columns, mean; bars, standard error of mean; n, sample size; P, overall probability values. #, ## and ###: P < .05, .01, and .001, respectively, compared with control.